Hemab Therapeutics Holdings, Inc. Common Stock (COAG) vs Inhibrx Biosciences Inc. (INBX)
A side-by-side comparison of Hemab Therapeutics Holdings, Inc. Common Stock and Inhibrx Biosciences Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
COAG
Hemab Therapeutics Holdings, Inc. Common Stock
$28.37HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
INBX
Inhibrx Biosciences Inc.
$93.41HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — COAG vs INBX
growth of $100 · dividends reinvested · last 1yCOAG -10.0% (-10.0%/yr)INBX -26.6% (-26.6%/yr)COAG compounded faster over this window
COAG INBX
COAG vs INBX: by the numbers
- •INBX is the larger company ($1.37B vs $1.33B market cap).
- •Both run net losses; COAG's is the smaller (0.00% vs -10773.46% net margin).
Metrics side by side
Valuation
| Metric | COAG | INBX |
|---|---|---|
| P/B ratio | 2.92 | N/A |
Profitability
| Metric | COAG | INBX |
|---|---|---|
| Gross margin | 0.00% | -91.00% |
| Operating margin | 0.00% | -10386.54% |
| Net margin | 0.00% | -10773.46% |
| ROIC | -38.09% | -99.35% |
Growth (annualized)
| Metric | COAG | INBX |
|---|---|---|
| Total return CAGR (5Y) | N/A | 27.64% |
Go deeper
Dig into the metrics
Hemab Therapeutics Holdings, Inc. Common Stock ROEInhibrx Biosciences ROEHemab Therapeutics Holdings, Inc. Common Stock operating marginInhibrx Biosciences operating marginHemab Therapeutics Holdings, Inc. Common Stock revenue growthInhibrx Biosciences revenue growthHemab Therapeutics Holdings, Inc. Common Stock free cash flowInhibrx Biosciences free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.